The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...
Lonapegsomatropin statistically significantly reduced trunk percent fat at week 38 compared with placebo (-1.7% vs 0.4%, respectively) in adult GHD patients. The Food and Drug Administration (FDA) has ...
SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] "We are delighted to have secured TGA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback